Alkermes (ALKS) Change in Accured Expenses (2010 - 2026)
Alkermes' (ALKS) quarterly Change in Accured Expenses came in at $41.2 million in Q2 2026, down 22.67% year-over-year from $53.3 million in Q2 2025, and up 134.47% quarter-over-quarter from -$119.5 million in Q1 2026.
Analysis
Alkermes (ALKS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Change in Accured Expenses for 17 consecutive years, with $41.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Change in Accured Expenses fell 22.67% year-over-year to $41.2 million in Q2 2026; TTM through Jun 2026 was -$33.5 million, a 46630.56% decrease from a year earlier, with the FY2025 full-year figure at $100.9 million, up 274.05% from the prior year.
- Change in Accured Expenses was $41.2 million for Q2 2026 at Alkermes, up from -$119.5 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $73.0 million in Q4 2025 and troughed at -$119.5 million in Q1 2026.
- A 5-year average of $176833.3 and a median of $3.0 million in 2022 frame the typical range for Change in Accured Expenses.
- The widest YoY moves for Change in Accured Expenses: up 1119.45% in 2024, down 8516.2% in 2024.
- Over 5 years, Change in Accured Expenses stood at $3.1 million in 2022, then sank by 34.05% to $2.1 million in 2023, then surged by 1119.45% to $25.0 million in 2024, then surged by 191.99% to $73.0 million in 2025, then plunged by 43.6% to $41.2 million in 2026.
- The last three Change in Accured Expenses figures came in at $41.2 million (Q2 2026), -$119.5 million (Q1 2026), and $73.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 2.32 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 1.20 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | - |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 55.78 Mn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -204.33 Mn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -4.00 Mn |
| 10 | Alkermes | 7.58 Bn | 6.92 Bn | 397.90 Mn | 41.19 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 41.19 Mn |
| Mar 31, 2026 | -119.47 Mn |
| Dec 31, 2025 | 73.03 Mn |
| Sep 30, 2025 | -28.25 Mn |
| Jun 30, 2025 | 53.26 Mn |
| Mar 31, 2025 | 2.85 Mn |
| Dec 31, 2024 | 25.01 Mn |
| Sep 30, 2024 | -81.05 Mn |
| Jun 30, 2024 | 36.52 Mn |
| Mar 31, 2024 | -38.45 Mn |
| Dec 31, 2023 | 2.05 Mn |
| Sep 30, 2023 | 963,000.00 |
| Jun 30, 2023 | 50.15 Mn |
| Mar 31, 2023 | -30.15 Mn |
| Dec 31, 2022 | 3.11 Mn |
| Sep 30, 2022 | 33.23 Mn |
| Jun 30, 2022 | 12.61 Mn |
| Mar 31, 2022 | -33.41 Mn |
| Dec 31, 2021 | -4.03 Mn |
| Sep 30, 2021 | 68.18 Mn |